RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Picton Mahoney Asset Management

Picton Mahoney Asset Management lifted its stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 994.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,175 shares of the company’s stock after purchasing an additional 14,697 shares during the quarter. Picton Mahoney Asset Management’s holdings in RAPT Therapeutics were worth $26,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Medicxi Ventures Management Jersey Ltd acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $35,316,000. Los Angeles Capital Management LLC grew its position in RAPT Therapeutics by 9.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock worth $348,000 after acquiring an additional 18,558 shares during the period. Callan Family Office LLC purchased a new position in RAPT Therapeutics in the fourth quarter worth approximately $92,000. SG Americas Securities LLC grew its position in RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock worth $84,000 after acquiring an additional 42,636 shares during the period. Finally, Barclays PLC grew its position in RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares during the period. Institutional investors and hedge funds own 99.09% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of RAPT Therapeutics in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.29.

RAPT Therapeutics Stock Down 1.8 %

RAPT opened at $1.12 on Tuesday. RAPT Therapeutics, Inc. has a 52 week low of $0.79 and a 52 week high of $9.65. The business has a fifty day simple moving average of $1.19 and a 200-day simple moving average of $1.50. The firm has a market cap of $39.15 million, a P/E ratio of -0.40 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69). Sell-side analysts expect that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.